Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691856 | 0.84 | RAB9A (0.62) | NAMPTALDH1A1SMN1; SMN2KDM1ARCOR1 | |
| SCHEMBL16691884 | 0.83 | NAMPT (0.60) | NAMPTALDH1A1SMN1; SMN2KDM1ARCOR1 | |
| SCHEMBL16693559 | 0.83 | RAB9A (0.54) | ALDH1A1SMN1; SMN2KDM1ARCOR1LMNA | |
| SCHEMBL31022619 | 0.79 | NAMPT (0.66) | NAMPTALDH1A1SMN1; SMN2KDM1ARCOR1 | |
| SCHEMBL19541138 | 0.77 | NAMPT (0.69) | NAMPTALDH1A1SMN1; SMN2KDM1ARCOR1 | |
| SCHEMBL16693603 | 0.76 | NAMPT (0.64) | NAMPTALDH1A1SMN1; SMN2HSD17B10LMNA | |
| SCHEMBL13947029 | 0.74 | NAMPT (1.00) | NAMPTLMNAHIF1ANPC1RAB9A | |
| SCHEMBL18407900 | 0.74 | HTT (0.52) | NAMPTALDH1A1SMN1; SMN2HSD17B10LMNA | |
| SCHEMBL3940458 | 0.73 | BRAF (0.63) | NAMPTCYP11B2 | |
| SCHEMBL790322 | 0.73 | NAMPT (0.71) | NAMPTLMNAHIF1ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321774-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | CHRM1, CHRM2, CHRM3 | NAMPT 4373/4885ALDH1A1 3148/4885SMN1; SMN2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.